GAITHERSBURG, Md. -- (BUSINESS WIRE) -- MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at Cambridge Health Institute’s BioProcessing Summit to be held August 19-23, 2013, at the Renaissance Boston Waterfront Hotel in Boston, MA. MaxCyte will present data in a scientific podium presentation emphasizing the use of MaxCyte flow electroporation for the rapid production of antibodies and antibody-like molecules at extremely high titers, as well as high-efficiency downstream generation of stable cell lines. In addition, MaxCyte will illustrate the use of its MaxCyte STX and MaxCyte VLX systems throughout the biotherapeutic development process including the production of bi-specific antibodies, recombinant proteins, VLPs, and viral vectors in two technical posters. MaxCyte scientists will be available throughout the conference at Booth #16 to demonstrate the operation of the MaxCyte STX and MaxCyte VLX instruments and to provide further technical details about the use of flow electroporation for large scale transient gene expression and rapid stable cell line generation.
Dr. James Brady, Director of Technical Applications at MaxCyte, will present data on flow electroporation in a podium presentation entitled “Scaling Pre-clinical Development to Biomanufacturing: Large Scale CHO Transient Transfection Using Flow Electroporation” on Friday, August 23, at 12:30 PM, within the Early IND Strategies: Process and Production scientific track.
“Industry leaders are migrating towards the use of transient gene expression for all stages of biotherapeutic programs. MaxCyte has led the way in demonstrating how flow electroporation can provide a rapid and reliable platform for production of multi-gram quantities of proteins to meet those needs,” says Douglas Doerfler, President and CEO of MaxCyte. “Dr. Brady’s conference presentation highlights how MaxCyte transfection streamlines early development and bioproduction scale-up, including efficient generation of stable cell lines. This unmatched capability is instrumental in reducing the time and cost constraints of biotherapeutic development.”
MaxCyte will also present two scientific posters, both available for viewing during the conference. The first poster, entitled “Bioproduction Using Flow Electroporation Systems: Gram/Liter Antibody Production via Transient Gene Expression (TGE) Through Rapid, High Yield Stable Cell Line Generation,” highlights the application of MaxCyte transfection throughout the antibody development pipeline by spanning small and large scale transient gene expression all the way to the generation of high yield stable cell lines. The second poster, entitled “Universal, Fully Scalable Transfection Platform for Production of Complex or Difficult-to-Express Proteins: Superior Performance over Other Transfection Methods & Expression Systems,” summarizes data demonstrating the utility of the MaxCyte platform for development of a variety of biotherapeutic formats including antibodies, bi-specific antibodies, recombinant proteins, and VLPs.
“MaxCyte flow electroporation is a unifying technology with the ability to span R&D through biomanufacturing needs,” says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. “In recent forums, we have presented and continue to highlight the use of flow electroporation for the production of multiple grams of antibodies using the MaxCyte STX. The MaxCyte VLX® Large Scale Transfection System brings the scalability of flow electroporation to the next level with the capability to transfect the equivalent of a 100-200 liter bioreactor in less than 30 minutes without any chemical or viral components that can compromise product quality or expression. This combination of performance, flexibility, and scalability truly sets MaxCyte flow electroporation apart from other transfection methods.”
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information, http://www.maxcyte.com.